Tag Archives: T-cell receptor

Mallinckrodt Acquires Therakos for $1.33 Billion – Cellex Treatment System

Therakos’ Cellex extracorporeal photopheresis system is used to administer autologous immune cell therapy for the treatment of cutaneous T-cell lymphoma (CTCL), the two most common forms of which include mycosis fungoides (up to 20,000 case per year in the US) and Sézary Syndrome, which is an aggressive form of the disease.  in total, CTCL’s account for less than 4% of all non-Hodgkins lymphomas. Continue reading

Immunocor’s Anti-Cancer Platform Garners $320MM Private Financing

Immunocor raised $320MM in a private financing round to support its anti-cancer platform. That’s a lot of money for a single financing – in fact, it is the largest private fundraising by a European biotechnology company. What’s the attraction? Continue reading